Edwards Lifesciences (EW) Tops Q1 EPS by 5c; offers guidance

Edwards Lifesciences (NYSE: EW) reported Q1 EPS of $0.78, $0.05 better than the analyst estimate of $0.73. Revenue for the quarter came in at $1.65 billion versus the consensus estimate of $1.6 billion.

GUIDANCE:

Edwards Lifesciences sees Q2 2026 EPS of $0.70-$0.76, versus the consensus of $0.75. Edwards Lifesciences sees Q2 2026 revenue of $1.66-1.74 billion, versus the consensus of $1.683 billion.

Edwards Lifesciences sees FY2026 EPS of $2.95-$3.05, versus the consensus of $2.97. Edwards Lifesciences sees FY2026 revenue of $6.5-6.9 billion, versus the consensus of $6.675 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
• Caldwell sells IQTalent subsidiary to WinMil for C$4.7M
• AI-powered cyber threats light a fire under cybersecurity stocks